Title: A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Authors: Sch√∂ffski, Patrick ×
Awada, Ahmad
Dumez, Herlinde
Gil, Thierry
Bartholomeus, Sylvie
Wolter, Pascal
Taton, Martine
Fritsch, Holger
Glomb, Patricia
Munzert, Gerd #
Issue Date: Jan-2012
Publisher: Pergamon
Series Title: European Journal of Cancer vol:48 issue:2 pages:179-186
Abstract: Volasertib (BI 6727) is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk). This phase I dose-escalation study evaluated the maximum tolerated dose (MTD) of volasertib, safety and efficacy, and pharmacokinetic (PK) parameters.
ISSN: 0959-8049
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science